Abstracts - PAGE Meeting (Population Approach Group Europe)

← Back to filters

Abstracts (114)

IV-001Mark Sale

Announcement of Machine Learning Benchmarking

Thursday 15:00-16:45

IV-002Eric Salgado

A population pharmacokinetic model of obeldesivir in healthy subjects and patients with COVID-19

Thursday 15:00-16:45

IV-003Sergio Sánchez Herrero

A Novel Approach to Drug Release Dose Optimization using PhysPK® and Machine Learning

Thursday 15:00-16:45

IV-004Aymara Sancho Araiz

Model reductions of a physiologically-based pharmacokinetic model for intestinal and hepatic first pass metabolism: towards derivation of a generalized bioavailability model using midazolam as case example

Thursday 15:00-16:45

IV-005Harshbir Singh Sandhu

Development of a framework for mechanistic modelling and interspecies scaling for AAV gene therapy

Thursday 15:00-16:45

IV-006Suchaya Sanhajariya

Exploring tidyvpc, an efficient and versatile toolkit for performing visual predictive checks (VPCs) in pharmacometrics models.

Thursday 15:00-16:45

IV-007Mohammed Rohi Sanoufi

Population pharmacokinetics of intravenous linezolid in critically ill paediatric patients

Thursday 15:00-16:45

IV-008Celine Sarr

Application of Model-Informed Drug Development for Dose Optimization of Brigimadlin in Patients with Dedifferentiated Liposarcoma

Thursday 15:00-16:45

IV-009Tomohiro Sasaki

QSP modeling of OPB-171775, a PDE3A-SLFN12 molecular glue to predict clinical respose in patients with gastrointestinal stromal tumor (GIST).

Thursday 15:00-16:45

IV-010Adriana Savoca

A mechanistic framework for interpretation and prediction of the PKPD/anti-tumour activity relationship of irreversible Tyrosine Kinase Inhibitors (TKIs) targeting EGFR Exon20Ins mutation

Thursday 15:00-16:45

IV-011Sharon Sawe

Population pharmacokinetic modelling as a screening tool to expedite evidence for hard-to-study populations: a case study of atazanavir/ritonavir in people with HIV.

Thursday 15:00-16:45

IV-012Ahenk Zeynep Sayin

A Physiologically-Based Computational Model of Bilirubin Metabolism: Integrating Real-World Data for Enhanced Clinical Evidence

Thursday 15:00-16:45

IV-013Stephan Schaller

Development of an End-to-End Quantitative Model-Informed Drug Development (MIDD) Ecosystem

Thursday 15:00-16:45

IV-014Carmine Schiavone

Unveiling the Kinetics of Immunity: Mechanistic Insights into COVID-19 Vaccine Responses and Population Stratification

Thursday 15:00-16:45

IV-015Verena Schöning

Simulation of virtual pharmacometric patient profiles using generative artificial intelligence

Thursday 15:00-16:45

IV-016Jiyoung Seo

Repeated time-to-events model of Nausea and Vomiting induced by Efpeglenatide

Thursday 15:00-16:45

IV-017Raju Prasad Sharma

A Minimal Physiologically based pharmacokinetic Framework Incorporating Antigen Shedding Dynamics for Optimizing Immuno-Oncology Therapies

Thursday 15:00-16:45

IV-018Sanaya Shroff

NMsim: Seamless NONMEM Simulation Platform in R

Thursday 15:00-16:45

IV-019Hanna Silber Baumann

Confirming pharmacokinetic properties of satralizumab using a bodyweight tiered dosing regimen in LUMINESCE, a phase 3 study for generalized Myasthenia Gravis

Thursday 15:00-16:45

IV-020Myra Skerlep

Model-Based Approach for a New Prolonged-Release (PR) Formulation of Ivabradine: PK and PKPD Assessment to Support Bioequivalence

Thursday 15:00-16:45

IV-021Erin H. Smeijsters

Population pharmacokinetic model for a local sustained-release hydrogel formulation containing bupivacaine for the postoperative pain management after spinal surgery.

Thursday 15:00-16:45

IV-022Jisoo Song

A population pharmacokinetic model of abiraterone with a mixed zero-order and first-order absorption kinetics in healthy Korean volunteers

Thursday 15:00-16:45

IV-023Seoghwa Song

Comparative analysis of target-mediated drug disposition model and conventional compartment model in Biologics: Analysis of Pharmacokinetic by real case-based model simulations

Thursday 15:00-16:45

IV-024Meemansa Sood

Population time-activity modeling and simulation supporting the reduced dosimetry collection for radioligand therapy (RLT) clinical trials

Thursday 15:00-16:45

IV-025Tomás Sou

Horseshoe prior as a fast and efficient approach for covariate selection in pharmacometric modelling

Thursday 15:00-16:45

IV-026Felix Stader

Physiologically based pharmacokinetic modelling to predict antibody exposure in patients with hepatic impairment

Thursday 15:00-16:45

IV-027Sofia Stathopoulos

Integrating PKPD and disease progression machine learning models for predicting late phase study outcome based on early phase biomarker data – an oncology example on the InSilicoTrials’ simulation platform

Thursday 15:00-16:45

IV-028Juliane Staudinger

Covariate Analysis of Metabolizing Enzymes and Efflux Transporters and Model based Therapeutic Drug Monitoring in Females Receiving Olaparib

Thursday 15:00-16:45

IV-029Marylise Sterlé

Linking Abemaciclib Exposure and Early Toxicity in HR+/HER2- Breast Cancer Patients: Insights from Real-World Data

Thursday 15:00-16:45

IV-030Julia Stolk

A Quantitative Systems Pharmacology Model to Investigate the Crucial Role of Epithelial Damage in the Pathogenesis of Inflammatory Bowel Disease

Thursday 15:00-16:45

IV-031Ming Sun

LeiCNS-PK3.2: A Physiologically Based Pharmacokinetic Model Incorporating Active Brain Membrane Transport—Insights into Intracellular Exposure of Acyclovir and Ganciclovir Active Metabolites

Thursday 15:00-16:45

IV-032Jugal Suthar

Improving Predictive Accuracy in Vincristine PopPK Models Through Model Averaging and Dataset Augmentation

Thursday 15:00-16:45

IV-033Jérémie Tachet

Optimizing ruxolitinib therapy using a population approach: insights from a real-world prospective observational study

Thursday 15:00-16:45

IV-034Michael Tagen

Generalized FOCE for Discrete Response Models with Pumas

Thursday 15:00-16:45

IV-035Chrisoula Tahtsidou

Population pharmacokinetics of orally administered letermovir in real world allogeneic hematopoietic cell transplantation recipients

Thursday 15:00-16:45

IV-036Tadao Tamura

Performance validation for models translated between development software and commercial healthcare platforms

Thursday 15:00-16:45

IV-037Zhiyuan Tan

Advancing 5-FU precision dosing: external PK model evaluation, generic PK model development, novel limited sampling strategies and fit-for-use shiny application

Thursday 15:00-16:45

IV-038Lénaïg Tanneau

Assessment of Phase 1 pharmacokinetic-pharmacodynamic predictions, based on Phase 3 clinical trials results.Depemokimab pharmacokinetics and response in blood eosinophil count reduction for asthma and chronic rhinosinusitis with nasal polyps patients

Thursday 15:00-16:45

IV-039Alaric Taylor-roffey

Thursday 15:00-16:45

IV-040Ileana Theofili

Predicting VEGF Levels in Cancer Patients Using Machine and Deep Learning

Thursday 15:00-16:45

IV-041Charlotte M Thomas

Pharmacokinetics of Flucytosine in HIV-positive adults with cryptococcal meningitis adults in Africa

Thursday 15:00-16:45

IV-042Johannes Tillil

Patients with chronic inflammatory diseases experience higher exposure of small-molecule drugs than healthy volunteers: A population PK model-focused analysis of recently approved drugs

Thursday 15:00-16:45

IV-043Gilles Tiraboschi

Population PK/PD Modeling to Predict Efficacy of Extended Dosing of Amlitelimab in Moderate-to-Severe Atopic Dermatitis Patients

Thursday 15:00-16:45

IV-044Dominic Tong

Evaluation of population pharmacokinetic model predictive performance in adults on hemodialysis treated with vancomycin

Thursday 15:00-16:45

IV-045Mario Torchia

Population PKPD analysis of preclinical data to inform clinical study design for a platelet derived hemostatic agent

Thursday 15:00-16:45

IV-046Elena Maria Tosca

Translating Preclinical Insights into Clinical Outcomes: A Predictive Framework for Overall response rate and time to progression in Solid Tumors

Thursday 15:00-16:45

IV-047Elias Toulitsis

Analysis of the absorption processes using the top-down PBFTPK models Impact on the bottom up PBPK modeling work

Thursday 15:00-16:45

IV-048Armando Tratenšek

Target-mediated drug disposition model of ustekinumab in patients with ulcerative colitis

Thursday 15:00-16:45

IV-049Athanasios Tsekouras

FTPK (Finite Time Pharmacokinetic) software for the analysis of pharmacokinetic data

Thursday 15:00-16:45

IV-050Lufina Tsirizani

Population pharmacokinetics of first-line TB drugs in Haitian children under 5 years old, and accuracy of finger stick capillary sampling technique.

Thursday 15:00-16:45

IV-051Periklis Tsiros

Modelling Pharmacokinetic Variability with Physics-Informed Neural Networks

Thursday 15:00-16:45

IV-052Anastasia Tsyplakova

Optimizing Mycophenolate Therapy in Renal Transplant Patients Using Machine Learning and Population Pharmacokinetic Modeling

Thursday 15:00-16:45

IV-053Yaroslav Ugolkov

Quantitative systems pharmacology model of B-cell immune response

Thursday 15:00-16:45

IV-054Martin Umpierrez

preDose: An R-Package for Robust External Evaluation of PopPKPD Models Prior to Implementation in Real-Time MIPD

Thursday 15:00-16:45

IV-055Parth J. Upadhyay

An r Shiny application for the projection of dose ranges in preclinical and first in human clinical studies during the early stages of drug development

Thursday 15:00-16:45

IV-056Séverine Urdy

PBPK modeling and simulation of the pharmacokinetics of an antibody drug conjugate in a patient population of phase I clinical trials

Thursday 15:00-16:45

IV-057Elodie Valade

Assessment of Vactosertib effect on QT interval: A Retrospective Concentration-QTc Analysis in Oncology Patients

Thursday 15:00-16:45

IV-058Diego Valderrama

Innovative Multimodal Neural ODE Modelling for Predicting Clinical Outcomes and Understanding Drug Treatment Effects in Inflammatory Bowel Disease

Thursday 15:00-16:45

IV-059Cristian Valiante

Defining Adult Dosing of Midazolam Oromucosal Solution for Prolonged Seizures Using Population PK Modeling

Thursday 15:00-16:45

IV-060Debra van Asten

Quantifying the exposure-toxicity relationship of [177Lu]Lu-PSMA-I&T using a population PK-PD model

Thursday 15:00-16:45

IV-061Hidde van de Beek

Aggregate data modeling in R: a new method for fitting pharmacometrics models to summary-level data

Thursday 15:00-16:45

IV-062Stefan Van Den Berg

One model to rule them all? A meta-analysis of therapeutic antibody population PK models.

Thursday 15:00-16:45

IV-063Jennie van Dyk

Pharmacokinetics of ritonavir-boosted atazanavir in children and adolescents with HIV: Analysis of CHAPAS-4 and VirTUAL trials

Thursday 15:00-16:45

IV-064Bart van Lieshout

A Model-Based Framework for Intracellular Pathogen Pharmacodynamics to Accelerate the Translation of Host-Directed Therapies

Thursday 15:00-16:45

IV-065Eline Van Maanen

Joint Exposure-Response Analysis of PET Amyloid Plaque Data from the BACE1 Inhibitor Verubecestat and Amyloid mAbs Trials Enhances the Understanding of Drug Effects

Thursday 15:00-16:45

IV-066Martijn Van Noort

A modeller’s perspective on EM methods versus FOCE in NONMEM

Thursday 15:00-16:45

IV-067Wisse van Os

A PK/PD workflow to support the selection of empirical antibiotic combination therapies: application to neonatal sepsis

Thursday 15:00-16:45

IV-068Daan W. Van Valkengoed

Model-based exploration of the P-glycoprotein concentration-activity relationship shows a drug and system dependency: implications for mechanistic PBPK modelling of active transporter activity

Thursday 15:00-16:45

IV-069Abraham Vaquero Castro

AI/ML algorithm for clinical data reconstruction: Turning AD into IPD.

Thursday 15:00-16:45

IV-070Sergei Vavilov

Model-based reproduction of receptor-targeting antibody pharmacodynamics allows to identify ligand turnover parameters

Thursday 15:00-16:45

IV-071Alberto Vegas Rodriguez

INTEGRATED POPULATION PKPD MODELLING OF VIRAL DYNAMICS AND HOST IMMUNE RESPONSE IN HIV PATIENTS UNDERGOING ANTIRETROVIRAL MONOTHERAPY

Thursday 15:00-16:45

IV-072Peter Velickovic

Do differences in pharmacokinetics overcome resemblances in immune system characteristics in cynomolgus macaques for the evaluation of antitubercular drugs?

Thursday 15:00-16:45

IV-073Esmee Vendel

Integrated PK-PD model relating serum copper concentrations, urinary copper clearance and trientine pharmacokinetics in Wilson Disease: initial insights from the UNITED study

Thursday 15:00-16:45

IV-074Umberto Villani

In vitro-in silico characterisation of host-directed therapeutics combined with antimicrobials in tuberculosis

Thursday 15:00-16:45

IV-075Marco Virgolin

Optimal Sampling Design of Clinical Trials Using Multi-Objective Genetic Algorithms

Thursday 15:00-16:45

IV-076Vo Thanh

Effective Dosage Regimens Selection Based-on PK/PD Targets within Simcyp Framework

Thursday 15:00-16:45

IV-077Alina Volkova

Model-based meta-analysis of targeted therapies in systemic lupus erythematosus and its manifestations

Thursday 15:00-16:45

IV-078Thanakorn Vongjarudech

Evaluation of Cross-Validation in Pharmacometrics Model Selection

Thursday 15:00-16:45

IV-079Dimitrios Voulgarelis

Translational PK/PD-Efficacy modelling for camizestrant (SERD)

Thursday 15:00-16:45

IV-080Chenyu Wang

Evaluating the Relationship Between Experimental EC50 Values and Mechanism-Based Model Parameters in Viral Dynamics models

Thursday 15:00-16:45

IV-081Qianwen Wang

Population Pharmacokinetics Modelling of Ibrexafungerp Using Data from Healthy Volunteers

Thursday 15:00-16:45

IV-082Tianqi Wang

Leveraging Machine Learning to Decode Polymeric Long-Acting Injectables and Predict Their Performance

Thursday 15:00-16:45

IV-083Xiaoning (Shelly) Wang

Population Pharmacokinetic Analysis of Emtricitabine in Adolescents and Children with HIV-1

Thursday 15:00-16:45

IV-084Yan Wang

Alternative Model-Based Dosing Strategies for Subcutaneous Nivolumab to Improve Cost-Effectiveness in NSCLC Patients

Thursday 15:00-16:45

IV-085Linda Wanika

Uncertainty quantification in Mixed effects modelling

Thursday 15:00-16:45

IV-086Eva Wehrhahn

Bacterial morphology-based pharmacokinetic-pharmacodynamic models of carbapenem-exposed Gram-negative bacteria

Thursday 15:00-16:45

IV-087Gustaf Wellhagen

Predictors of ability to work in multiple sclerosis

Thursday 15:00-16:45

IV-088Haini Wen

A pulmonary population PBPK model for sampling design evaluation

Thursday 15:00-16:45

IV-089Manon Wigbers

Applications of Quantitative Systems Pharmacology (QSP) Modelling for Vaccine Development

Thursday 15:00-16:45

IV-090Mélanie Wilbaux

Population Pharmacokinetic Analysis Supporting Fixed and Extended-Interval Dosing of Balstilimab Alone and Combined with Botensilimab in Advanced Solid Tumors

Thursday 15:00-16:45

IV-091Sandra Witta

Evaluation of a model averaging algorithm for model informed precision dosing in the context of parameter misspecifications

Thursday 15:00-16:45

IV-092Kacper Wnuk

Pharmacokinetic Modeling of Ticagrelor in the Presence of Morphine in Healthy Volunteers

Thursday 15:00-16:45

IV-093Daniel Wojtyniak

Parameter Significance Test Using Mixture Models (PaSTUM) allowing Type-1 Error Control for Exposure Response Modelling

Thursday 15:00-16:45

IV-094Jen-Hao Wu

Population modeling to exploit Phase I dose-finding trials data in pediatric oncology exemplified by brigatinib (ITCC-098) and bosutinib (ITCC-054)

Thursday 15:00-16:45

IV-095Maria Xiberras

Repeated time to event modelling of morphine pharmacodynamics for analgesia after paediatric cardiac surgery

Thursday 15:00-16:45

IV-096Nuo Xu

Population pharmacokinetics of total and unbound concentrations of intravenous caspofungin in Chinese critically ill pediatric patients

Thursday 15:00-16:45

IV-097Ling Xue

Dynamic interaction modeling of adalimumab and anti-drug antibodies in ankylosing spondylitis

Thursday 15:00-16:45

IV-098Aysenur Yaliniz

Population Pharmacokinetic Modeling of Amoxicillin in Penguins

Thursday 15:00-16:45

IV-099Liang Yang

Impacts of different aggregation methods and dropout types on MBMA models

Thursday 15:00-16:45

IV-100Tianwu Yang

Development of A Population Pharmacokinetic Model of Busulfan in Pediatric Patients

Thursday 15:00-16:45

IV-101Risa Yokokawa

Mathematical modeling of immune response following mRNA- or protein-based vaccine for SARS-CoV-2

Thursday 15:00-16:45

IV-102Dr Kenta Yoshida

BayesERtools: R package for exposure-response analysis with Bayesian approaches

Thursday 15:00-16:45

IV-103Raiki Yoshimura

Prediction of Disease Progression in Acute Liver Injury Patients Using Machine Learning and Mathematical Modeling

Thursday 15:00-16:45

IV-104huifang you

Using machine learning with longitudinal data to forecast 2-month biomarker response using phase 2a information

Thursday 15:00-16:45

IV-105Javier Zarzoso-Foj

PBBM of ibuprofen enantiomers in tablets: in silico exploration of bioequivalence studies design

Thursday 15:00-16:45

IV-106Mengxu Zhang

Predicting Clozapine Brain Extracellular Pharmacokinetics in Rat and Human: Integrating Brain Metabolism, Active Influx Transport and Accumulation in Neutral Lipids in the LeiCNS PBPK Model

Thursday 15:00-16:45

IV-107Renwei Zhang

Model-based meta-analysis of combination drug effects to evaluate drug effect independency and interaction effects

Thursday 15:00-16:45

IV-108Shengyuan Zhang

A mechanistic model describing antibody response and SARS-CoV-2 viral loads

Thursday 15:00-16:45

IV-109Wei Zhang

Impact of assay on the predictive performance of model-informed precision dosing of ustekinumab in patients with Crohn’s disease

Thursday 15:00-16:45

IV-110Qiaolin Zhao

Population PK Analysis of Infliximab in Young Pediatric IBD Patients: Label-Recommended Dose Fails to Achieve Therapeutic Target Concentration

Thursday 15:00-16:45

IV-111Aole Zheng

Model-informed Precision Dosing of Endogenous Hormones: Focusing on Progesterone and Estradiol

Thursday 15:00-16:45

IV-112Jin Zhou

Population Pharmacokinetic Analysis of Seladelpar in Patients with Primary Biliary Cholangitis

Thursday 15:00-16:45

IV-113Xiao Zhu

A Semi-Mechanistic Population Pharmacokinetic Model of Linezolid in ICU Patients with Renal Impairment: Optimizing Dosing for Effective Urinary Tract Infections Treatment

Thursday 15:00-16:45

IV-114Yuanxi Zou

QT interval prolongation in children receiving moxifloxacin and clofazimine for rifampicin-resistant tuberculosis treatment in South Africa, India, and the Philippines

Thursday 15:00-16:45